share_log

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $34

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $34

Wedbush维持对Kiniksa Pharmaceuticals的跑赢大盘评级,并将其目标股价上调至34美元。
Benzinga ·  07/23 12:55  · 评级/大行评级

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $30 to $34.

Wedbush分析师David Nierengarten坚持认为Kiniksa Pharmaceuticals(纳斯达克股票代码:KNSA)表现优异,将价格目标从30美元升至34美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发